serine palmitoyltransferase long chain base subunit 1Genealiases: ALS27 · HSAN1 · HSN1 · LBC1 · LCB1 · SPT1
Q-omics provides the consensus-scored SPTLC1 profile across patient tissues and cancer cell-line models. SPTLC1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPTLC1 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, SPTLC1 RNA expression shows 20,132 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BLCA, and ACC as cancer lineages where SPTLC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPTLC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPTLC1 survival associations across molecular data types. SPTLC1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPTLC1 RNA expression–survival associations across cancer types. High SPTLC1 expression shows unfavorable associations in ACC, CESC, BLCA, SCLC and PAAD, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPTLC1 RNA expression.
This table summarizes SPTLC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SPTLC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPTLC1 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in BLCA, CHOL and STAD. The BLCA box plot shows higher SPTLC1 RNA expression in tumor versus normal tissue (log2 FC = +0.817, t-test p < 0.001).
This table shows molecular features associated with SPTLC1 in patient tissues and cancer cell lines. In patient samples, SPTLC1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SPTLC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
